Medpace Holdings, Inc.
MEDPAPI behind this page
MEDP FY 2025 request
Playground key active
/api/financials?ticker=MEDP&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 2,530,234 | 2,109,054 | +20.0% |
Show Product Lines breakouts |
|||
| AVAI | 254,838 | 181,977 | +40.0% |
| Cardiology | 134,935 | 156,460 | -13.8% |
| Central Nervous System | 239,371 | 230,454 | +3.9% |
| Metabolic | 408,548 | 431,384 | -5.3% |
| Oncology | 747,585 | 651,237 | +14.8% |
| Other | 744,957 | 457,542 | +62.8% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 2,530,234 | 2,109,054 | +20.0% |
Show Counterparty Name breakouts |
|||
| CinRx Pharma and Subsidiaries · Revenue net | 45.3 | 28.3 | +60.1% |
| LIB · Revenue net | 7.9 | 21.7 | -63.6% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 53.2 | 50 | +6.4% |
| Direct Operating Costs | 1,769,616 | 1,452,749 | +21.8% |
Show Product Lines breakouts |
|||
| Direct Costs | 732,128 | 682,095 | +7.3% |
| Reimbursed out-of-pocket expenses | 1,037,488 | 770,654 | +34.6% |
| Reimbursed out-of-pocket expenses · Reportable Segment | 1,037,488 | 770,654 | +34.6% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 1,769,616 | 1,452,749 | +21.8% |
| Selling, General & Administrative | 197,559 | 180,184 | +9.6% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 197,559 | 180,184 | +9.6% |
| Depreciation | 27,178 | 27,808 | -2.3% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 27,178 | 27,808 | -2.3% |
| Amortization Of Intangible Assets | 946 | 1,443 | -34.4% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 946 | 1,443 | -34.4% |
| Total Costs & Expenses | 1,995,299 | 1,662,184 | +20.0% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 1,995,299 | 1,662,184 | +20.0% |
| Operating Income | 534,935 | 446,870 | +19.7% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 534,935 | 446,870 | +19.7% |
| Other Non-Operating Income (Expense) | -5,338 | 4,056 | -231.6% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | -5,338 | 4,056 | -231.6% |
| Interest Income Expense Nonoperating Net | 12,780 | 24,996 | -48.9% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 12,780 | 24,996 | -48.9% |
| Non-Operating Income (Expense) | 7,442 | 29,052 | -74.4% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 7,442 | 29,052 | -74.4% |
| Income Before Taxes | 542,377 | 475,922 | +14.0% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 542,377 | 475,922 | +14.0% |
| Income Tax Expense (Benefit) | 91,254 | 71,536 | +27.6% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 91,254 | 71,536 | +27.6% |
| Net Income | 451,123 | 404,386 | +11.6% |
Show Business Segments breakouts |
|||
| Reportable Segment · Operating Segments | 451,123 | 404,386 | +11.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 451,123 | 404,386 | +11.6% |
| EPS (Basic) | 15.64 | 13.06 | +19.8% |
| EPS (Diluted) | 15.28 | 12.63 | +21.0% |
| Wtd Avg Shares (Basic) | 28,846 | 30,957 | -6.8% |
Show Equity Components breakouts |
|||
| Common Stock | 28,846 | 30,957 | -6.8% |
| Wtd Avg Shares (Diluted) | 29,527 | 32,014 | -7.8% |
| Comprehensive Income | 460,960 | 399,715 | +15.3% |
| Labor And Related Expense (FY) | — | — | — |
Show Product Lines breakouts |
|||
| Direct Costs · Reportable Segment | 588,786 | 545,417 | +8.0% |
| Net Income Loss Available To Common Stockholders Basic | 451,123 | 404,342 | +11.6% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 497,049 | 669,436 | -25.8% |
| Receivables Net Current | 402,078 | 296,443 | +35.6% |
Show Counterparty Name breakouts |
|||
| CinRx Pharma and Subsidiaries · Related Party Service Agreement | 1.6 | 1.4 | +14.3% |
| LIB · Related Party Service Agreement | 1.9 | 2.8 | -32.1% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 3.5 | 4.2 | -16.7% |
| Prepaid Expenses & Other Current Assets | 90,497 | 63,350 | +42.9% |
| Total Current Assets | 989,624 | 1,029,229 | -3.8% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 131,055 | 123,615 | +6.0% |
Show Geography breakouts |
|||
| Asia Pacific | 14,910 | 14,552 | +2.5% |
| BE | 22,998 | 18,557 | +23.9% |
| Europe | 29,820 | 26,013 | +14.6% |
| Europe, Other | 6,822 | 7,456 | -8.5% |
| Other | 2,427 | 2,358 | +2.9% |
| US | 83,898 | 80,692 | +4.0% |
| Operating Lease Right-of-Use Assets | 117,815 | 128,649 | -8.4% |
Show Counterparty Name breakouts |
|||
| Chief Executive Officer And Immediate Family · Building | 4.2 | 6.4 | -34.4% |
| Chief Executive Officer And Immediate Family · Building | 0 | 0.7 | -100.0% |
| Chief Executive Officer And Immediate Family · Office Space | 48.4 | 50.2 | -3.6% |
Show Related Party Transaction breakouts |
|||
| Leased Real Estate · Chief Executive Officer | 15.8 | 17.6 | -10.2% |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 49,399 | 53,760 | -8.1% |
| Related Party | 68,416 | 74,889 | -8.6% |
| Goodwill | 662,396 | 662,396 | 0.0% |
| Deferred Tax Assets | 19,223 | 100,357 | -80.8% |
| Other Non-Current Assets | 21,939 | 22,254 | -1.4% |
| Total Assets | 1,975,472 | 2,100,866 | -6.0% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level3 · Fair Value Measurements Nonrecurring | 694 | — | — |
| Intangible Assets | 1,774 | 2,720 | -34.8% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 33,420 | 34,366 | -2.8% |
| Current Liabilities | |||
| Accounts Payable | 28,142 | 32,528 | -13.5% |
Show Related Party Transaction breakouts |
|||
| Travel Services · Related Party | 0.3 | 0.2 | +50.0% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 0.3 | 0.2 | +50.0% |
| Accrued Liabilities | 408,382 | 307,807 | +32.7% |
| Deferred Revenue (Current) | 854,390 | 710,585 | +20.2% |
Show Counterparty Name breakouts |
|||
| CinRx Pharma and Subsidiaries · Related Party Service Agreement | 4.3 | 5.2 | -17.3% |
| LIB · Related Party Service Agreement | 8.1 | 9.5 | -14.7% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 12.3 | 14.6 | -15.8% |
| Other Liabilities Current | 52,834 | 53,633 | -1.5% |
| Total Current Liabilities | 1,343,748 | 1,104,553 | +21.7% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 113,643 | 126,234 | -10.0% |
Show Counterparty Name breakouts |
|||
| Chief Executive Officer And Immediate Family · Building | 1.9 | 4.2 | -54.8% |
| Chief Executive Officer And Immediate Family · Building | 0.5 | 1.5 | -66.7% |
| Chief Executive Officer And Immediate Family · Office Space | 60.2 | 62 | -2.9% |
Show Related Party Transaction breakouts |
|||
| Leased Real Estate · Chief Executive Officer | 14.7 | 16.5 | -10.9% |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 36,299 | 41,975 | -13.5% |
| Related Party | 77,344 | 84,259 | -8.2% |
| Deferred Tax Liabilities | 1,355 | 1,800 | -24.7% |
| Other Non-Current Liabilities | 57,655 | 42,734 | +34.9% |
| Total Liabilities | 1,516,401 | 1,275,321 | +18.9% |
| Stockholders' Equity | |||
| Common Stock | 284 | 306 | -7.2% |
| Treasury Stock Common Value | -12,156 | -12,235 | +0.6% |
| Additional Paid In Capital Common Stock | 935,830 | 844,050 | +10.9% |
| Retained Earnings | -459,981 | 8,167 | -5732.2% |
| Accumulated Other Comprehensive Income | -4,906 | -14,743 | +66.7% |
| Total Stockholders' Equity | 459,071 | 825,545 | -44.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -4,906 | -14,743 | +66.7% |
| Additional Paid In Capital | 935,830 | 844,050 | +10.9% |
| Common Stock | 284 | 306 | -7.2% |
| Retained Earnings | -459,981 | 8,167 | -5732.2% |
| Treasury Stock Common | -12,156 | -12,235 | +0.6% |
| Total Liabilities & Equity | 1,975,472 | 2,100,866 | -6.0% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 34,786 | 25,514 | +36.3% |
Show Income Statement Location breakouts |
|||
| Selling General And Administrative Expenses | 21,174 | 14,397 | +47.1% |
| Total direct costs | 13,612 | 11,117 | +22.4% |
| Operating Lease Right Of Use Asset Amortization Expense | 23,014 | 23,124 | -0.5% |
| Deferred Income Taxes And Tax Credits | 80,773 | -26,632 | +403.3% |
| Other Non-Cash Items | -875 | -4,009 | +78.2% |
| Increase Decrease In Receivables | -106,215 | 2,242 | -4837.5% |
| Change in Prepaid & Other Assets | -27,101 | -12,090 | -124.2% |
| Change in Accounts Payable | 2,629 | -2,965 | +188.7% |
| Increase Decrease In Accrued Liabilities | 97,083 | 16,882 | +475.1% |
| Change in Deferred Revenue | 143,805 | 150,725 | -4.6% |
| Increase Decrease In Operating Lease Liability | -25,160 | -21,407 | -17.5% |
| Increase Decrease In Other Operating Capital Net | 11,237 | 23,794 | -52.8% |
| Net Cash from Operations | 713,223 | 608,815 | +17.1% |
| Deferred Income Taxes | 80,917 | -26,622 | +403.9% |
| Investing Activities | |||
| Capital Expenditures | -31,356 | -36,548 | +14.2% |
| Other Investing Activities | 216 | 8,240 | -97.4% |
| Net Cash from Investing | -31,140 | -28,308 | -10.0% |
| Financing Activities | |||
| Proceeds From Stock Options Exercised | 57,001 | 15,858 | +259.4% |
| Share Repurchases | -917,389 | -169,867 | -440.1% |
Show Share Repurchase Program breakouts |
|||
| 2022 Share Repurchase Program | -912.9 | -174.2 | -424.1% |
| Net Cash from Financing | -860,388 | -154,009 | -458.7% |
| Supplemental | |||
| Income Taxes Paid | 39,719 | 83,567 | -52.5% |
| Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 | 1,645 | 4,984 | -67.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5,918 | -2,511 | +335.7% |
| Net Change in Cash | -172,387 | 423,987 | -140.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 497,049 | 669,436 | -25.8% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.